Jane Street
OVID icon

Jane Street’s Ovid Therapeutics OVID Stock Holding History

Jane Street’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-735,429
Closed -$1.63M – 12706
2026
Q1 		$1.63M Sell
735,429
-148,438
-17% -$265K ﹤0.01% 5470
2025
Q4 		$1.44M Buy
883,867
+645,452
+271% +$994K ﹤0.01% 5398
2025
Q3 		$310K Buy
238,415
+95,818
+67% +$83K ﹤0.01% 8838
2025
Q2 		$47K Buy
+142,597
New +$43K ﹤0.01% 9191
2025
Q1 		– Sell
-14,278
Closed -$13.3K – 10298
2024
Q4 		$13.3K Sell
14,278
-24,121
-63% -$27K ﹤0.01% 9162
2024
Q3 		$45.3K Sell
38,399
-60,191
-61% -$62.9K ﹤0.01% 9196
2024
Q2 		$75.8K Buy
98,590
+45,010
+84% +$125K ﹤0.01% 8823
2024
Q1 		$163K Buy
53,580
+2,679
+5% +$8.96K ﹤0.01% 8296
2023
Q4 		$164K Buy
+50,901
New +$174K ﹤0.01% 8348
2023
Q2 		– Sell
-108,615
Closed -$280K – 9322
2023
Q1 		$280K Buy
108,615
+49,497
+84% +$117K ﹤0.01% 7309
2022
Q4 		$110K Buy
59,118
+45,030
+320% +$76.7K ﹤0.01% 8040
2022
Q3 		$26K Buy
14,088
+2,674
+23% +$5.59K ﹤0.01% 9131
2022
Q2 		$25K Sell
11,414
-52,094
-82% -$126K ﹤0.01% 9111
2022
Q1 		$199K Buy
+63,508
New +$200K ﹤0.01% 9033
2021
Q3 		– Sell
-76,973
Closed -$301K – 10511
2021
Q2 		$301K Buy
76,973
+36,862
+92% +$145K ﹤0.01% 8143
2021
Q1 		$161K Buy
+40,111
New +$133K ﹤0.01% 8419
2020
Q4 		– Sell
-35,087
Closed -$201K – 7939
2020
Q3 		$201K Buy
35,087
+5,632
+19% +$37.7K ﹤0.01% 6428
2020
Q2 		$217K Sell
29,455
-24,006
-45% -$112K ﹤0.01% 6266
2020
Q1 		$160K Buy
+53,461
New +$180K ﹤0.01% 4754
2019
Q3 		– Sell
-52,309
Closed -$97K – 5557
2019
Q2 		$97K Buy
52,309
+34,850
+200% +$62.2K ﹤0.01% 4861
2019
Q1 		$31K Buy
+17,459
New +$43.7K ﹤0.01% 4874

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jane Street's OVID Position: Q2 2026 in Review

Jane Street sold out of Ovid Therapeutics (OVID) in Q2 2026, closing a stake of 735,429 shares — an estimated $1.63M sold.

Jane Street first reported a position in OVID in Q1 2019 and held it in 21 quarters. The position peaked at $1.63M in Q1 2026. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Jane Street reported no remaining Ovid Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 735,429 Ovid Therapeutics shares in Q2 2026, an estimated $1.63M.
  • Jane Street first reported a position in Ovid Therapeutics in Q1 2019 and held it in 21 quarters.
  • Jane Street's Ovid Therapeutics position peaked at $1.63M in Q1 2026.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.